Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...

Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...

The National Pharmaceutical Pricing Authority aims to hold drug manufacturers solely accountable for the excessive pricing of essential med...

Given the possibility of hostilities resuming in the Gulf region, focus on risk management in the market. Why? Because fresh hostilities wi...

In a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer s...

Here’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two stren...

What is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...

2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...

A word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...

The ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for pso...

The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSourc...

Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...